Gem Aromatics LimitedChemicalsGEMAROMA
Q1 FY27 concall · earnings callGem Aromatics Limited
A seasonally soft quarter was impacted by clove supply disruptions, while the focus remains on ramping up higher-margin specialty products at the new Dahej facility to drive future growth.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue (Standalone) | ₹83 Cr | — | |
| Revenue (Consolidated) | ₹99 Cr | — | |
| Gross Profit (Standalone) | ₹14.7 Cr | — | |
| Gross Margin (Standalone) | 17.7% | — | |
| EBITDA (Standalone) | ₹8.5 Cr | — | |
| EBITDA Margin (Standalone) | 10.3% | — | |
| Gross Profit (Consolidated) | ₹16.5 Cr | — | |
| Gross Margin (Consolidated) | 16.7% | — |
TL;DR
- Revenue grew year-on-year but was seasonally soft.
- Clove business disrupted by Madagascar floods, affecting raw material supply and cost.
- New Dahej facility (Krystal) is in commercialization phase; key milestones include customer approvals and initial orders.
- Consolidated loss due to high depreciation and operating costs before new products fully contribute.
- Meaningful revenue from new product verticals (cooling agents, Safranal, phenol) expected to ramp from Q3/Q4 FY27.
- Management expects Krystal products to be over 50% of overall revenue by FY28.
Said on the call
“We are entering an important phase of progressive scale-up with emphasis on improving utilization, strengthening our product portfolio, and deepening customer relationships across our markets.”
From the Q&A
| Topic | What management said |
|---|---|
| Demand and Growth | Management stated demand is strong and back to normal levels, with the Western Hemisphere (US, Latin America) ramping up. Q1 is historically a softer quarter. |
| Krystal/New Product Timeline | Cooling agents: initial orders secured, meaningful contribution expected from Q3 FY27. Safranal: revenue contribution expected from end of Q2 FY27, more meaningful from Q3 FY27. Phenol derivatives: trial production by end of Q2 FY27, commercial production targeted for Q3 FY27, meaningful revenue from Q4 FY27. |
| Clove Business Disruption | Floods in Madagascar in Q1 delayed raw material shipments for 30 days due to port closure. Supply has resumed from May, but shipping challenges persist. |
| Margin Drivers and Recovery | Margins were impacted by product mix, higher clove RM costs, and new plant operating costs. Recovery key drivers are production ramp-up and shift to higher-value specialty products. Krystal products expected to be over 50% of revenue by FY28. |
| Path to Profitability | Consolidated loss due to timing mismatch: high depreciation (INR9.1 Cr) and operating costs from the new Dahej facility are booked, but revenue from higher-margin Krystal products is yet to come. Profitability will improve as new products commercialize. |
| Growth Trajectory | FY27 is a ramp-up year focused on commercializing new verticals; meaningful ramp-up and significant volumes expected in FY28. Management declined to give specific revenue or margin guidance for FY27. |
| Cooling Agent Capacity | Management expects to be fairly close to 25% capacity utilization (on 500-ton capacity) for cooling agents by Q3/Q4 FY27, pending shipping challenges. |
Guidance
- Cooling agents: meaningful revenue contribution expected from Q3 FY27.
- Safranal: revenue contribution expected towards end of Q2 FY27, more meaningful from Q3 FY27.
- Phenol derivatives: commercial production targeted during Q3 FY27, meaningful revenue contribution expected from Q4 FY27.
- FY27 is a ramp-up year for new product verticals; meaningful ramp-up and significant volumes expected in FY28.
- Krystal products expected to be more than 50% of overall revenue by FY28.
Source
Summary written from the transcript filed by Gem Aromatics Limited for the call held on 14 Aug 2026; published 20 Aug 2026, 16:33 IST.
More Q1 FY27 concalls ·How verification works ·Report an error